Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scaling Busulfan Dose to Body Surface Area in Children Undergoing HSCT
NCT07792369Phase 1Not yet recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of busulfan in hematopoietic stem cell transplantation (HSCT) (2 arms), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Number of participants who achieve a therapeutic drug exposure after the first dose of Busulfan at 1 day. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
busulfan
03
Conditions
hematopoietic stem cell transplantation (HSCT)
Beyond the preview
Go deeper on NCT07792369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792369.